Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies-Reference-Cited by-同舟云学术

Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies

Published:2023-12 Issue: Volume: Page:
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Sawaya Ghady Bou-Nehme,Dragomir Alice,Wood Lori A.,Kollmannsberger Christian,Basappa Naveen S.,Kapoor Anil,Soulières Denis,Finelli Antonio,Heng Daniel Y.C.,Castonguay Vincent,Canil Christina,Winquist Eric,Graham Jeffrey,Bjarnason Georg A.,Bhindi Bimal,Lalani Aly-Khan,Pouliot Frédéric,Breau Rodney H.,Saleh Ramy,Tanguay Simon

Funder

McGill University

Publisher

Elsevier BV

Subject

Urology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference18 articles.

1. Sarcomatoid renal cell carcinoma: biology, natural history and management;Blum;Nat Rev Urol,2020

2. Renal cell carcinoma with sarcomatoid features: finally new therapeutic hope?;Pichler;Cancers,2019

3. Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021;Christina Canil;Can Urol Assoc J,2021

4. Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma;Rini;J Immunother Cancer,2022

5. Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER;Motzer;J Clin Oncol,2021

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic study of the CDKN2A and CDKN2B genes in renal cell carcinoma patients;Practical Laboratory Medicine;2024-05

2. Prognostic Value of the Lung Immune Prognostic Index on Recurrence after Radical Surgery for High-Risk Renal Cell Carcinoma;Cancers;2024-02-14